» Articles » PMID: 34679580

A Machine Learning Application to Predict Early Lung Involvement in Scleroderma: A Feasibility Evaluation

Overview
Specialty Radiology
Date 2021 Oct 23
PMID 34679580
Citations 10
Authors
Affiliations
Soon will be listed here.
Abstract

Introduction: Systemic sclerosis (SSc) is a systemic immune-mediated disease, featuring fibrosis of the skin and organs, and has the greatest mortality among rheumatic diseases. The nervous system involvement has recently been demonstrated, although actual lung involvement is considered the leading cause of death in SSc and, therefore, should be diagnosed early. Pulmonary function tests are not sensitive enough to be used for screening purposes, thus they should be flanked by other clinical examinations; however, this would lead to a risk of overtesting, with considerable costs for the health system and an unnecessary burden for the patients. To this extent, Machine Learning (ML) algorithms could represent a useful add-on to the current clinical practice for diagnostic purposes and could help retrieve the most useful exams to be carried out for diagnostic purposes.

Method: Here, we retrospectively collected high resolution computed tomography, pulmonary function tests, esophageal pH impedance tests, esophageal manometry and reflux disease questionnaires of 38 patients with SSc, applying, with R, different supervised ML algorithms, including lasso, ridge, elastic net, classification and regression trees (CART) and random forest to estimate the most important predictors for pulmonary involvement from such data.

Results: In terms of performance, the random forest algorithm outperformed the other classifiers, with an estimated root-mean-square error (RMSE) of 0.810. However, this algorithm was seen to be computationally intensive, leaving room for the usefulness of other classifiers when a shorter response time is needed.

Conclusions: Despite the notably small sample size, that could have prevented obtaining fully reliable data, the powerful tools available for ML can be useful for predicting early lung involvement in SSc patients. The use of predictors coming from spirometry and pH impedentiometry together might perform optimally for predicting early lung involvement in SSc.

Citing Articles

Biomarkers in Systemic Sclerosis: An Overview.

Di Maggio G, Confalonieri P, Salton F, Trotta L, Ruggero L, Kodric M Curr Issues Mol Biol. 2023; 45(10):7775-7802.

PMID: 37886934 PMC: 10604992. DOI: 10.3390/cimb45100490.


Pulmonary Nodules in Juvenile Systemic Sclerosis: A Case-Series from the National Registry for Childhood Onset Scleroderma (NRCOS).

Li J, Tadros S, Rosser F, Torok K Diagnostics (Basel). 2023; 13(12).

PMID: 37370998 PMC: 10297561. DOI: 10.3390/diagnostics13122103.


Beyond Henssge's Formula: Using Regression Trees and a Support Vector Machine for Time of Death Estimation in Forensic Medicine.

Dani L, Toth D, Frigyik A, Kozma Z Diagnostics (Basel). 2023; 13(7).

PMID: 37046478 PMC: 10093024. DOI: 10.3390/diagnostics13071260.


Development and validation of machine learning for early mortality in systemic sclerosis.

Foocharoen C, Thinkhamrop W, Chaichaya N, Mahakkanukrauh A, Suwannaroj S, Thinkhamrop B Sci Rep. 2022; 12(1):17178.

PMID: 36229500 PMC: 9563044. DOI: 10.1038/s41598-022-22161-9.


Prediction model for the pretreatment evaluation of mortality risk in anti-melanoma differentiation-associated gene 5 antibody-positive dermatomyositis with interstitial lung disease.

Gui X, Li W, Yu Y, Zhao T, Jin Z, Meng K Front Immunol. 2022; 13:978708.

PMID: 36211445 PMC: 9539924. DOI: 10.3389/fimmu.2022.978708.


References
1.
Desai S, Veeraraghavan S, Hansell D, Nikolakopolou A, Goh N, Nicholson A . CT features of lung disease in patients with systemic sclerosis: comparison with idiopathic pulmonary fibrosis and nonspecific interstitial pneumonia. Radiology. 2004; 232(2):560-7. DOI: 10.1148/radiol.2322031223. View

2.
Doyle T, Dellaripa P, Batra K, Frits M, Iannaccone C, Hatabu H . Functional impact of a spectrum of interstitial lung abnormalities in rheumatoid arthritis. Chest. 2013; 146(1):41-50. PMC: 4077411. DOI: 10.1378/chest.13-1394. View

3.
Denton C, Khanna D . Systemic sclerosis. Lancet. 2017; 390(10103):1685-1699. DOI: 10.1016/S0140-6736(17)30933-9. View

4.
Herzog E, Mathur A, Tager A, Feghali-Bostwick C, Schneider F, Varga J . Review: interstitial lung disease associated with systemic sclerosis and idiopathic pulmonary fibrosis: how similar and distinct?. Arthritis Rheumatol. 2014; 66(8):1967-78. PMC: 4340472. DOI: 10.1002/art.38702. View

5.
Distler O, Highland K, Gahlemann M, Azuma A, Fischer A, Mayes M . Nintedanib for Systemic Sclerosis-Associated Interstitial Lung Disease. N Engl J Med. 2019; 380(26):2518-2528. DOI: 10.1056/NEJMoa1903076. View